by Truveta staff | Apr 21, 2025 | Research
Asthma is one of the most studied chronic diseases in medicine, yet decades into the biologics era, researchers face familiar frustrations. Limited phenotyping, unpredictable treatment responses, persistent health disparities, and slow insight cycles can’t meet...
by Truveta Research | Apr 18, 2025 | Research, Research Insights
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in March 2025 increased relative to December 2024 (+12.96%). Anti-diabetic medication (ADM) prescribing increased from December 2024 to January 2025, then remained relatively stable until March...
by Truveta staff | Apr 15, 2025 | Research, Research Insights
Authors: Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Patricia D. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Charlotte Baker, DrPH, MPH, CPH ⊕Truveta, Inc,...
by Truveta Research | Apr 3, 2025 | Research, Research Insights
The vaccination rate by age six fluctuated between 2018 and 2021; however, rates have decreased since 2021. The rate in 2021 was 81.9% compared to 80.4% in 2024. This means for every 70 children, roughly one more child received two measles vaccines in 2021 compared to...
by Truveta Research | Apr 3, 2025 | Research, Research Insights
Measles vaccination rates for children under 24 months in 2024 remain lower than in 2020. In 2024, the average yearly measles vaccination rate for children by 13 months was 58.9% and 68.5% for children by 15 months. Vaccination patterns for children living in both...
by Truveta staff | Apr 1, 2025 | Research
GLP-1 drugs like Ozempic and Zepbound are transforming obesity treatment, yet 40-85% of patients are plagued by adverse GI events—particularly women. New research from Olio Labs, using Truveta Data, reveals that women experience nausea and vomiting at significantly...
